Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.
Read More
1 minute read

Centers For Medicare & Medicaid Services Approves Transitional Pass-through Reimbursement Status For Harrow’s Iheezo (Chloroprocaine Hydrochloride Ophthalmic Gel) 3% For Ocular Surface Anesthesia

By Benzinga Newsdesk
Today, 3:38 AM
Beginning April 1, 2023, and for the three years thereafter, IHEEZO will be eligible for separate reimbursement outside of the surgical bundled payment in both the Ambulatory Surgery Center (ASC) and Hospital

HROW

Read More
3 minute read

Melt Pharmaceuticals’ MELT-300, Midazolam 3mg And Ketamine 50mg Sublingual Tablet, Achieves Top-Line Results In Primary Sedation Endpoint In Phase 2 Pivotal Efficacy And Safety Study

By Benzinga Newsdesk
Today, 3:38 AM
  MELT-300 Statistically Superior for Procedural Sedation Compared to All Comparator Treatment Arms, Including Midazolam 3mg (P=0.0129) and Ketamine 50mg (P=0.0096) MELT-300 Treatment Arm 50% Less Likely to Require Rescue Sedation Compared to Midazolam (P=0.0198)

HROW